The collaboration with Partex NV to use AI for identifying and evaluating biopharmaceutical compounds could lead to new acquisitions or licensing deals, potentially enhancing Fortress Biotech's portfolio and growth prospects. This strategic move is likely to be viewed positively by investors, leading to a potential short-term increase in stock price.